The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
Open accessAbstract
Signal-detection algorithms (SDAs) are recognized as vital tools in pharmacovigilance. However, their performance characteristics are generally unknown. By leveraging a unique gold standard recently made public by the Observational Medical Outcomes Partnership (OMOP) and by conducting a unique systematic evaluation, we provide new insights into the diagnostic potential and characteristics of SDAs that are routinely applied to the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). We find that SDAs can attain reasonable predictive accuracy in signaling adverse events. Two performance classes emerge, indicating that the class of approaches that address confounding and masking effects benefits safety surveillance. Our study shows that not all events are equally detectable, suggesting that specific events might be monitored more effectively using other data sources. We provide performance guidelines for several operating scenarios to inform the trade-off between sensitivity and specificity for specific use cases. We also propose an approach and demonstrate its application in identifying optimal signaling thresholds, given specific misclassification tolerances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Stang, P. E., Ryan, P. B., Racoosin, J. A., Overhage, J. M., Hartzema, A. G., Reich, C., Welebob, E., Scarnecchia, T., & Woodcock, J. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-9-201011020-00010 · Cited by 441
Self-citationStatin safety: an appraisal from the adverse event reporting system
Davidson, M. H., Clark, J. A., Glass, L. M., & Kanumalla, A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.008 · Cited by 113
Cited by
Hoffman, K. B., Dimbil, M., Erdman, C. B., Tatonetti, N. P., & Overstreet, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0150-2 · Cited by 211
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
Cutroneo, P. M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., Moretti, U., et al. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1323057 · Cited by 224
Raschi, E., Gatti, M., Gelsomino, F., Ardizzoni, A., Poluzzi, E., & De Ponti, F. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00738-6 · Cited by 157
Raschi, E., Poluzzi, E., Salvo, F., Pariente, A., De Ponti, F., Marchesini, G., & Moretti, U. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.02.014 · Cited by 119
Raschi, E., Mazzarella, A., Antonazzo, I. C., Bendinelli, N., Forcesi, E., Tuccori, M., Moretti, U., Poluzzi, E., & De Ponti, F. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00632-w · Cited by 101
Metadata
- Authors
- Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P., & Shah, N. H.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-02-11
- Volume
- 93
- Issue
- 6
- Pages
- 539-546
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2107516065
- Cited by
- 333
- References
- 3
- FWCI
- 31.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System. https://app.cochat.ai/papers/10.1038/clpt.2013.24
- The paper
- Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P., & Shah, N. H. (2013). Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2013.24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.